CoChat

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis

Open access
Kawaguchi-Suzuki, Marina, Cusi, Kenneth, Bril, Fernando, Gong, Yan, Langaee, Taimour, Frye, Reginald F. · 2018 · Frontiers in Pharmacology
Cited by 31

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Pioglitazone is used effectively to treat nonalcoholic steatohepatitis (NASH), but there is marked variability in response. This study examined whether genetic variation contributes to pioglitazone response variability in patients with NASH. This genetic substudy includes 55 participants of a randomized controlled trial designed to determine the efficacy of long-term pioglitazone treatment in patients with NASH. The primary outcome of the clinical trial was defined as ≥ 2-point reduction in the nonalcoholic fatty liver disease activity score (NAS). In this substudy, single nucleotide polymorphisms (SNPs) in putative candidate genes were tested for association with primary and secondary outcomes. A genetic response score was constructed based on the sum of response alleles for selected genes. The genetic response score was significantly associated with achievement of the primary outcome (odds ratio 1.74; 95% CI 1.27-2.54; p=0.0015). ADORA1 rs903361 associated with resolution of NASH (p=0.0005) and change in the ballooning score among Caucasian and Hispanics patients (p=0.0005). LPL rs10099160 was significantly associated with change in ALT (p=0.0005). The CYP2C8*3 allele, which confers faster pioglitazone clearance in allele carriers, was associated with change in fibrosis score (p=0.026). This study identified key genetic factors that explain some of the inter-individual variability in response to pioglitazone among patients with NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2018.00752

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 31

Metadata

Authors
Kawaguchi-Suzuki, M., Cusi, K., Bril, F., Gong, Y., Langaee, T., & Frye, R. F.
Venue
Frontiers in Pharmacology
Published
2018-07-17
Volume
9
Pages
752-752
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2809629677
Cited by
31
References
6
FWCI
2.56
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.